NCI-H69/LX20

96042332, human lung, Not specified

• 分類程式碼代碼: 41106514

属性

• product name: NCI-H69/LX20, 96042332
• 生物源: human lung
• 增長模式: Aggregates in suspension
• 染色體組型: Not specified
• 形態學: Not specified
• 產品: Not specified
• 受體: Not specified
• 技術: cell culture | mammalian: suitable
• 相關疾病: cancer
• 運輸包裝: dry ice
• 儲存溫度: −196°C

说明

細胞系來源

Human Caucasian small cell lung carcinoma

細胞系描述

The drug-resistant cell line NCI-H69/LX20 has been derived by exposure of the parent line, H69 (ECACC Number 91091802) to doxorubicin, also known as adriamycin. These multi drug resistant (MDR) cells have been found to be recognised by various anti-P-glycoprotein antibodies.

應用

Analysis of acquired drug resistance, study of small cell lung carcinoma, MDR studies.

培養基

RPMI 1640 + 2mM Glutamine + 2μg/ml Doxorubicin + 10% Foetal Bovine Serum (FBS). ECACC has found that the following supplement will assist good growth of cells: sodium selenite 10nM, Insulin 250ng/ml, Transferrin 10ug/ml and sodium pyruvate 1mM.

例行更新培養

Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO₂; 37°C. It is recommended to culture the cells without drug upon resuscitation until the first passage. Resuscitate into 9 ml of medium. Immediately after resuscitation perform a centrifugation ste

其他說明

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.